Posted in | News | Plastics and Polymers

GlaxoSmithKline to Look at Using OBJ's Enhanced Transdermal Polymer Material

OBJ Limited wishes to announce that it has entered into a short term arrangement with GlaxoSmithKline Consumer Healthcare (GSK) during which GSK will be funding and carrying out exploratory studies to investigate the potential use of OBJ's transdermal drug delivery technology, Dermaportation, for a range of nonprescription healthcare applications.

This arrangement follows a small exploratory study with GSK last year which suggested that OBJ's Dermaportation technology may increase delivery of a specific drug through the skin.

OBJ's Dermaportation technology, and its new Enhanced Transdermal Polymer material, enhance transdermal (through the skin) drug delivery. The technology is applicable to a broad range of drugs and drug delivery environments including applications where chemical and other approaches are unsuitable or unreliable. Transdermal delivery provides a convenient, effective and patient friendly method of drug delivery for both locally acting and systemic drugs.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.